Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

The causes of cachexia: key signals and the brain

Cachexia is a systemic condition of progressive weight loss and muscle and adipose tissue wasting, often seen in cancer and associated with poor prognosis. This Review explores the connection between circulating signalling factors and the brain in the development of cachexia and argues for the importance of pathways within the brain as both drivers of key features of cancer cachexia and promising therapeutic targets.

Medicine Without Drugs: An Israeli Breakthrough in Nanomedicine

A research team from the Technion’s Wolfson Faculty of Chemical Engineering has developed an original technology for treating cancer using nanoparticles that carry no drugs at all, and has demonstrated its effectiveness against particularly dangerous and stubborn tumors.

Nvidia scandal may test fragile US-China truce, experts say

U.S. Commerce Dept looks to cut off China’s current ability to remotely control Nvidia chips outside China.

The geopolitical stakes around frontier AI compute just escalated significantly. 🏛️⚡️

While physical hardware embargoes (restricting shipping A100/H100/H200 accelerators to Chinese destinations) have been active under U.S. Export Administration Regulations (EAR), enforcing remote cloud access remained a major enforcement friction point.

Here is the breakdown of why this shift is happening now:

1. The Compute-as-a-Service Loophole.

Chinese AI labs and tech entities have routinely leased compute clusters housed in neutral or third-party jurisdictions (e.g., Southeast Asian cloud nodes). Because the silicon physically resides outside China, no raw hardware crosses restricted borders—yet foreign engineers execute training runs remotely.

2. Shift in Lobbying Dynamics.

Nvidia has historically pushed back against broad export bans to protect global commercial revenue and maintain market presence. However, following recent intelligence reports and congressional inquiries into data-center intermediaries (like Megaspeed), Capitol Hill’s appetite for tighter enforcement has expanded.

Retatrutide Reduces Knee Osteoarthritis Pain and Weight, Improves Physical Function

The investigational triple incretin agonist drug retatrutide was associated with significant improvement in knee osteoarthritis (OA) pain and physical function along with weight loss in people with painful knee osteoarthritis and obesity, data from two phase 3 trials showed.

“We saw very exciting amounts of pain reduction and function improvement over time. I think this is a big advance… Osteoarthritis has lacked effective therapies for so long,” study investigator Philip Conaghan, MBBS, PhD, director of the NIHR Biomedical Research Centre in Leeds and professor of musculoskeletal medicine at the University of Leeds, United Kingdom, told Medscape Medical News.

The data came from Eli Lilly’s TRIUMPH-4 trial, of once-weekly retatrutide in different doses compared with placebo for 68 weeks, and TRIUMPH-1-OA, a substudy of a larger trial investigating the triple GLP-1, GIP, and glucagon receptor agonist for treating obesity. Conaghan presented results from TRIUMPH-4 on November 8, 2026, and will present the TRIUMPH-1-OA data on November 10, 2026, both at the American College of Rheumatology (ACR) 2026 Annual Meeting in Orlando, Florida.

GLP-1 drugs getting new labels warning of rare vision-loss condition

All GLP-1 drugs, which include popular brands like Ozempic and Wegovy, will soon carry new labels warning people taking the medications about a possible side effect that could lead to permanent vision loss.

Why you should care:

The Food and Drug Administration explained the labels will alert patients to a potential eye condition known as non-arteritic anterior ischemic optic neuropathy. While doctors do not know what causes the rare condition, it can lead to decreased blood flow through the optic nerve.